NEW YORK (GenomeWeb) – UK-based liquid biopsy firm Angle said today that it has inked a comarketing agreement with Qiagen for circulating tumor cell (CTC) technology.
Under the terms of the agreement, the companies will market Angle's Parsortix system for harvesting CTCs alongside Qiagen's liquid biopsy product portfolio, including its next-generation sequencing, PCR, single-cell analysis, and bioinformatics products.
The companies will initially focus on prostate and breast cancer research applications, Angle said.
Angle's Parsortix system automates the processing of whole blood to harvest all types of CTCs, including clinically relevant mesenchymal CTCs, and complements Qiagen's AdnaTest CTC portfolio, enabling phenotypic and molecular characterization of CTCs, Michael Kazinski, senior director of molecular preanalytic technologies at Qiagen, said in a statement.
"We believe the ability to offer customers a combination of Parsortix with validated and reliable downstream analysis technologies from … Qiagen facilitates key aspects of the sales cycle and we look forward to working closely together," Angle Founder and CEO Andrew Newland added.